Fungal acne: the full therapy pathway

The condition is real; the name is not medical. Dermatologists call it Malassezia folliculitis, or pityrosporum folliculitis in older writing, and both names describe it more accurately — the organism is a yeast rather than a mould, and the condition is inflammation of hair follicles rather than acne. The popular name stuck because it describes what people see and because it made the condition findable, which is genuinely useful. It also causes confusion, because it implies a relationship to acne that mostly runs the other way: acne treatment tends to make this worse.

The underlying science is sound and the way it is applied is often overdone. Malassezia cannot make its own fatty acids and must take them from its environment, so it feeds on many of the lipids used in skincare while being unable to use squalane, mineral oil or petrolatum. Choosing products on that basis while an eruption is active is reasonable. Treating a several-hundred-item avoidance list as permanent law is not — no clinical trial has shown that cosmetic avoidance alone prevents or treats this, and the anxiety the lists generate is a real cost for a fairly modest benefit.

That is one of the more useful clues on this page. Oral antibiotics reduce the bacterial population on skin, and the yeast that causes this condition competes with those bacteria — so removing the competition can let it overgrow. An eruption that worsened during a course of antibiotics prescribed for acne is a recognised pattern and a reasonable prompt to ask whether the diagnosis is right. Do raise it with the prescriber rather than stopping the course independently.

Probably not, and possibly the reverse. Benzoyl peroxide does kill Malassezia in laboratory conditions — that has been demonstrated directly — but the concentrations and contact conditions in a dish are not those of a wash on skin, and no clinical evidence shows it resolves this condition. Meanwhile it is irritating, and its antibacterial action reduces the competition the yeast faces. There is a much cheaper product two aisles over that is actually indicated for the organism.

Oral terbinafine will not work here, and the reason is genuinely interesting. It is an effective antifungal that does inhibit this yeast in the laboratory, but taken by mouth it does not reach adequate concentrations in the outermost layers of skin where Malassezia lives — a distribution problem rather than a spectrum problem. That was demonstrated directly: topical terbinafine suppressed the yeast while the oral drug essentially did not. Beyond that, taking leftover prescription antifungals is a poor idea for reasons that have nothing to do with this condition.

No — that is the expected behaviour, and reframing it is probably the most useful thing on this page. Malassezia is a normal resident of adult skin and nothing here eradicates it. Treatment reduces the population; the population recovers. The intervention that changes the pattern is intermittent maintenance — the same wash once or twice weekly, indefinitely — which almost nobody is told about, because the product is cheap and nobody is marketing it to you.

Yes, commonly, and it is the main reason facial cases are difficult. When both are present, treating one produces partial improvement that reads as failure, and some acne treatments make the folliculitis component worse. This is the situation where a clinician's assessment genuinely earns its keep, because getting the proportions right is not something that can be worked out reliably from a mirror.

Three features together: the bumps are uniform, they itch, and there are no blackheads. On a chest or back whose acne treatment is not working, that pattern is strong.

No single feature settles it, but three together do most of the work. Uniformity is the first: malassezia folliculitis produces crops of small papules and pustules that all look the same size and stage, rather than the mixed picture of acne where a blackhead sits beside a whitehead beside an inflamed lump. Itch is the second, and it is unusual enough in acne to be a genuine clue. The absence of comedones is the third and the most useful, because this condition does not produce blackheads at all. Add the typical territory, meaning upper back, chest and shoulders, and a treatment history of acne products that stopped working or made things worse, and the pattern is strong enough to justify a two-week trial of an antifungal wash. That trial is how most cases are confirmed in practice. The formal confirmation is a clinician looking at a follicular scraping under a microscope, which takes minutes.

Very possibly. Antibiotics remove the bacteria the yeast competes with, and this eruption classically appears or worsens during a course, especially one taken for acne.

Antibiotic exposure is one of the best-recognised triggers for this condition, and the mechanism is straightforward: the skin's bacterial population and Malassezia compete for the same territory and resources, so reducing one gives the other room. When the antibiotic was prescribed for what was assumed to be acne, the result is a loop that can run for years. The treatment produces the failure, the failure is read as severe acne, and more of the treatment follows. Breaking that loop is frequently the whole intervention. What this does not mean is that you should stop a prescribed antibiotic on the strength of a web page. Raise it with whoever prescribed it, describe what happened to your skin during the course, and ask whether the eruption might be folliculitis rather than acne. That is a reasonable and specific question. If the antibiotic was for something unrelated, the eruption often settles once the course finishes and the antifungal treatment is applied.

During an active eruption, avoiding metabolisable lipids over the area is sensible. As a permanent rule governing every product you own, it is far more than the evidence supports.

The underlying idea is sound. Malassezia cannot make its own fatty acids and metabolises certain chain lengths, so plant oils, many esters and some fatty alcohols applied over affected skin are a food supply. Removing that while you treat is reasonable and costs nothing. What has grown around that idea is a very large consumer category and an ingredient-avoidance culture that outruns what is known. Ingredient lists do not disclose concentration, so judging a formula safe from chain length alone is approximate at best. None of these products treat anything, and using them as though they do costs weeks. And the constraint tightens most where it matters least, on faces that are not affected, in maintenance periods, and on rinse-off products with seconds of contact. A workable position: be strict over the affected area while it is active, keep it loosely afterwards, and spend your attention on the medicated wash and the sweat and occlusion instead.

Several minutes, not seconds. Contact time is what kills the yeast, and rinsing immediately is the single commonest reason this appears not to work.

If you take one thing from this whole subject, take this. An antifungal wash lathered on and rinsed off in the normal way delivers almost no useful contact, and people then conclude the treatment failed when it was never really applied. The practical method is to make it the first thing and the last thing in the shower: apply to wet skin over the whole affected area at the start, then wash your hair, shave, do everything else, and rinse it off last. That naturally produces the several minutes the yeast needs to be exposed to the active. Set a timer if it helps. Two refinements. On the face, start with a shorter contact time and lower frequency than on the back, because facial skin tolerates these products far less well. And apply it across the whole affected zone rather than to individual bumps, since the follicles in between are involved and treating only what you can see leaves a reservoir.

Whichever your pharmacy stocks: ketoconazole 1%, selenium sulfide or zinc pyrithione. It is an anti-dandruff shampoo, used on the body, and it costs very little.

The treatment for this condition is not sold in the skincare aisle. It is a medicated shampoo, and the three actives worth looking for are ketoconazole, selenium sulfide and zinc pyrithione. Ketoconazole has the most direct evidence, since azoles specifically block the yeast's synthesis of ergosterol and its membrane fails; selenium sulfide and zinc pyrithione work less specifically but do reduce the population. Any of them is a reasonable first purchase, and availability should decide more than theory. A bottle costs a few pounds or dollars, lasts months, and is available without prescription in most countries. Two things matter far more than the brand on the bottle. Contact time, because applied and rinsed straight off it does very little. And using it over the whole affected area rather than dabbing individual bumps, since the follicles between them are involved too. Using a hair product on the body is off-label, which is normal practice here rather than a warning.

Visibly better inside a week and largely clear within two to four. This is the fastest-resolving condition on this site when the diagnosis is right.

Speed is one of the distinguishing features here, and it is genuinely useful information rather than reassurance. With correct use and adequate contact time, the itch usually settles first, often within a few days, and the bumps begin flattening in the first week. Two to four weeks takes most people to largely clear. That is fast enough that the fortnight functions as a diagnostic test as much as a treatment: a clear response is strong practical evidence for what this is. What lags behind is colour. Flat brown or red marks where bumps used to be are pigment rather than active disease, and they fade over months regardless of what you apply, so judging the treatment by whether the marks have gone leads to unnecessary extra weeks. Judge by texture instead, ideally with a photograph taken weekly under the same light, especially on a back you cannot see properly.

A long list. Itraconazole and fluconazole inhibit a major drug-metabolising enzyme, so they raise levels of many medicines, including some statins and sedatives.

Interactions are the main practical constraint on oral treatment here, more so than side effects. Both drugs inhibit cytochrome P450 3A4, which metabolises a very large share of common medicines, so levels of those drugs rise while the antifungal is on board. Categories that come up repeatedly include certain statins, where the combination raises the risk of muscle damage; some benzodiazepines and sedatives; several heart rhythm and blood pressure drugs; some immunosuppressants; certain anticoagulants; and some migraine, antipsychotic and HIV medicines. Hormonal contraception, oddly, is affected in the other direction from what people expect and is worth asking about specifically. Itraconazole absorption also depends on stomach acidity, so antacids and proton pump inhibitors reduce it. None of this is a reason to refuse treatment. It is a reason to hand the prescriber a complete list first, including over-the-counter medicines, herbal products and supplements, since St John's wort in particular interacts substantially.

Because it does not reach the skin surface in adequate concentration. The yeast is susceptible to it in the laboratory; the drug simply never gets to where it lives.

This is one of the more counterintuitive facts in dermatology and it catches out patients and prescribers alike. Terbinafine is a highly effective antifungal for nail and foot infections, and testing shows Malassezia is susceptible to it in vitro. Taken orally, however, it does not accumulate at the skin surface and within lipid-rich follicles at concentrations that matter, so it fails for pharmacokinetic reasons rather than because the organism resists it. Topical terbinafine, applied directly, is a different matter and can be useful. The practical consequences are worth holding onto. Leftover tablets from a nail infection are not a shortcut. If a clinician offers oral terbinafine for this specific diagnosis, it is reasonable to ask about itraconazole or fluconazole instead and to mention the reason. And a failed course of oral terbinafine is not evidence against the diagnosis, which is a mistake that can send an investigation off in the wrong direction entirely.

Topical treatment is the route in pregnancy. Ketoconazole and zinc pyrithione are poorly absorbed and often considered acceptable; oral antifungals are avoided.

Stated plainly: the plan stays topical during pregnancy, and the specifics belong with whoever is providing your antenatal care. Topical ketoconazole and zinc pyrithione have minimal systemic absorption, and short-contact use on the body is often considered acceptable, though none of these products is labelled for this condition and using a shampoo on the skin is off-label regardless of pregnancy. Selenium sulfide is the one most often avoided. Oral azole antifungals are a separate matter and are generally avoided, particularly in the first trimester. That is not a hardship here, because the treatments that carry no pregnancy implication at all are exactly the ones this condition responds to: removing sustained damp heat, showering promptly after sweating, changing out of damp clothing, choosing breathable fabrics, and using non-feeding emollients built on squalane, mineral oil or glycerin. Those carry proportionally more weight during pregnancy precisely because the medicated options are being used more cautiously. Confirm any specific product before starting.

The bumps are the same, but the redness reads as violet, grey or dark brown rather than pink, and pigment change is often what you notice first.

Inflammation in richly pigmented skin does not present as pink, so the classic description of small red papules and pustules translates poorly. What you see instead is texture plus colour change: uniform raised bumps that are dusky, violet, grey or deeper brown than surrounding skin, sometimes with the pigmentary aftermath more visible than the active lesions. On a chest or back under indoor lighting the raised element can be easy to miss entirely, which is one reason this is diagnosed late. Two adjustments help. Judge by touch and by itch rather than waiting for redness, since running a hand over the area detects uniform bumps regardless of colour. And photograph in daylight rather than under indoor bulbs, which flatten these changes further. The other consequence is that post-inflammatory hyperpigmentation is more prominent and longer-lasting here, so the marks left behind frequently distress people more than the eruption did and need to be understood as pigment rather than persistence.

Get out of damp kit and rinse within a reasonable window rather than hours later. The damp warm interval is the driver, not the exercise itself.

Nothing here is an argument against training. It is an argument about the twenty to ninety minutes afterwards, which is when a sweaty back inside a synthetic top provides exactly the warm humid environment this yeast multiplies in. The single highest-value change is shortening that interval: shower reasonably soon, or if that is not possible, change into a dry cotton top immediately and shower when you get home. During an active eruption, use the medicated wash on training days and give it proper contact time. A few smaller adjustments add up. Rinse rather than skipping a shower after light sessions. Take a spare shirt to work if you cycle or walk in. Do not sit in a car in wet kit. Wash gym clothes promptly rather than leaving them in a bag, which is about smell rather than reinfection but still worth doing. Backpacks and weight belts add occlusion and friction over precisely the territory that flares, so consider what is pressing on your back.

The same medicated wash, once or twice weekly, with the same contact time, indefinitely. About five minutes a week, and it is what prevents the annual cycle.

Maintenance is unglamorous and short, which is why people skip it and then experience this as a chronic condition. The standard version is the wash you cleared with, used once or twice a week on the areas that flare, left on for the same several minutes before rinsing, continued indefinitely. Contact time still matters on maintenance days; a rushed rinse achieves nothing whether it is weekly or daily. Around that sit the habits, which do at least as much work: showering promptly after sweating, changing out of damp clothing, breathable fabrics over the affected zones, and keeping heavy occlusive products off the chest and back. Two refinements worth building in. Step up to daily for a week or two ahead of a known trigger, meaning a hot season, a holiday, a training block or a course of antibiotics. And accept the smallest version you will genuinely keep, because a modest plan sustained beats an ideal one abandoned by spring.

Likely, if the conditions that permitted it are unchanged. The yeast is a permanent resident, so recurrence within months is normal rather than a treatment failure.

The honest expectation is fast clearance and a genuine likelihood of recurrence. Treatment reduces an overgrown population; it does not remove an organism that lives on everyone. So whether it returns depends much less on which product you used than on whether the heat, sweat, occlusion, antibiotic or medication that let it overgrow is still in place. People who understand that from the start tend to do well, because they set up maintenance instead of concluding after the second episode that nothing works. Three things reduce the odds meaningfully. A once-or-twice-weekly medicated wash continued indefinitely rather than stopped at clearance. Identifying and changing the specific driver, which for most people is two or three concrete habits rather than a lifestyle overhaul. And stepping maintenance up ahead of whatever season or training block usually sets it off. Recurrence within weeks despite genuine maintenance is a different matter and worth investigating rather than re-treating.

Stop self-treating and get it looked at. This condition responds fast, so four weeks of correct use with no change argues against the diagnosis rather than for a stronger dose.

The speed of response here is what makes a failed trial informative. When the diagnosis is right and the treatment is used properly, most people are visibly better inside a week. Four weeks with genuinely no change, after checking that contact time was adequate and that nothing was working against it, is better read as evidence against the diagnosis than as a reason to escalate. Continuing past that point is how people lose years to an eruption that was never this. What to do instead is a routine appointment rather than an urgent one, with a specific request: confirmation by microscopy of a follicular scraping, since the commonest finding in repeatedly treated cases is that the diagnosis was never confirmed. Bring exactly what you used, at what strength, how long it stayed on the skin, and for how many weeks, along with photographs of the eruption at its worst. The realistic alternatives are ordinary acne, bacterial folliculitis, keratosis pilaris, or a drug-induced eruption.

A quick scraping or tape lift from an affected follicle, prepared on a slide and examined for clusters of yeast. Mildly uncomfortable and nothing more.

This is the only procedure most people with this condition will ever have, and it is minor. A clinician takes material from an affected follicle, either by scraping the surface with a blade edge, by expressing the contents of a bump onto a slide, or by lifting the surface with adhesive tape. A drop of potassium hydroxide or a stain is added, and the slide goes under the microscope, where the characteristic round yeast cells are visible in clusters within follicular material. Scraping a follicle is mildly uncomfortable and nothing more, and where the equipment is to hand the result arrives during the appointment rather than weeks later. Culture is rarely used because Malassezia needs lipid-supplemented media most laboratories do not run. Two practical notes. Recent antifungal use can reduce yeast numbers enough to blunt the result, so say what you have used. And a negative result is informative rather than a failure, since it redirects the investigation.

That a formula avoids the fatty acids and esters this yeast can metabolise. It is a food-avoidance claim, not an antifungal one, and nothing on that list treats anything.

The term describes composition rather than effect. Malassezia cannot make its own fatty acids and metabolises a particular range of chain lengths, so a product built without those, typically relying on squalane, mineral oil, petrolatum, glycerin or silicones instead, gives it nothing to eat. That is genuinely useful for what goes on affected skin during an eruption. What it is not is treatment: a safe moisturiser does not reduce a yeast population, and using one as though it does costs weeks. Two limits worth holding. Ingredient lists do not disclose concentration, so judging safety from chain length alone is an approximation rather than a guarantee. And there is no regulatory definition or certification behind the phrase, so it means whatever the brand intends it to mean. Read the ingredient list rather than the claim. The purchase that changes the outcome is the medicated wash, which is sold as an anti-dandruff shampoo and is never labelled this way.